AVIR Atea Pharmaceuticals Inc.

34.07
+0.53  (+2%)
Previous Close 33.54
Open 35.76
52 Week Low 24.15
52 Week High 35.59
Market Cap $2,814,759,044
Shares 82,616,937
Float 74,951,988
Enterprise Value $2,624,611,800
Volume 581,776
Av. Daily Volume 0
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
AT-527
COVID-19
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
AT-752
Dengue
Phase 1
Phase 1
Phase 1 trial to be initiated 1H 2021.
AT-777
Hepatitis C
Phase 1/2
Phase 1/2
Phase 1/2a trial planned.

Latest News

  1. BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the appointment of Barbara Duncan to its Board of Directors, where she will also serve as Chair of the Audit Committee.

    "We are delighted to welcome Barbara to the Atea Board of Directors. Her financial acumen combined with her considerable experience advising a variety of biopharmaceutical companies will make Barbara's guidance invaluable to Atea as we navigate the public markets and advance our antiviral pipeline," said Jean-Pierre…

    BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the appointment of Barbara Duncan to its Board of Directors, where she will also serve as Chair of the Audit Committee.

    "We are delighted to welcome Barbara to the Atea Board of Directors. Her financial acumen combined with her considerable experience advising a variety of biopharmaceutical companies will make Barbara's guidance invaluable to Atea as we navigate the public markets and advance our antiviral pipeline," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea Pharmaceuticals.

    "I am proud to join Atea at this critical juncture as the Company recently transitioned to a publicly traded entity," said Ms. Duncan. "Importantly, I am excited to be a part of the team working to make a difference in this global pandemic through the advancement of AT-527, an oral product candidate for the treatment of patients suffering from COVID-19."

    Ms. Duncan previously served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals. Prior to her leadership role with Intercept, Ms. Duncan was Chief Financial Officer and then Chief Executive Officer at DOV Pharmaceutical, which was sold to Euthymics Bioscience. Before that, she served as Vice President of Corporate Finance - Global Healthcare at Lehman Brothers and as Director of Corporate Finance at SBC Warburg Dillon Read. Ms. Duncan currently serves on the Board of Directors of Adaptimmune Therapeutics, Fusion Pharmaceuticals, Jounce Therapeutics, ObsEva SA, and OVID Therapeutics.

    Ms. Duncan received an M.B.A. from the Wharton School, University of Pennsylvania and a B.S. from Louisiana State University.

    About Atea Pharmaceuticals

    Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company's deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, hepatitis C virus (HCV) infection, dengue virus, and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

    Contacts

    Investors:

    Will O'Connor

    Stern Investor Relations

    212-362-1200

    Media:

    Carol Guaccero

    301-606-4722

    View Full Article Hide Full Article
  2. BOSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the closing of its initial public offering of 14,375,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,875,000 additional shares of common stock, at a public offering price of $24.00 per share. The aggregate gross proceeds to Atea from the offering were $345 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares…

    BOSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the closing of its initial public offering of 14,375,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,875,000 additional shares of common stock, at a public offering price of $24.00 per share. The aggregate gross proceeds to Atea from the offering were $345 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Atea Pharmaceuticals. Atea's common stock began trading on the Nasdaq Global Select Market under the ticker symbol "AVIR" on October 30, 2020.

    J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Evercore Group L.L.C. and William Blair & Company, L.L.C. acted as joint book-running managers of the offering.

    A registration statement on Form S-1 (File No. 333-249404) relating to the offering has been filed with the Securities and Exchange Commission and became effective on October 29, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204; Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or by email at ; Evercore Group, L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by email at .

    This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    Contacts

    Investors:

    Will O'Connor

    Stern Investor Relations

    212-362-1200

    Media:

    Carol Guaccero

    301-606-4722

    View Full Article Hide Full Article
View All Atea Pharmaceuticals Inc. News